Topic: Merkel cell carcinoma
Merck’s latest Keytruda OK isn’t a huge one for the New Jersey pharma. But it’s a big deal for Bavencio drugmakers Pfizer and Merck KGaA.
After two recent trial flops, Pfizer and Merck KGaA are getting some good news around immuno-oncology contender Bavencio.
Pfizer and Merck KGaA’s Bavencio, which won an FDA nod for Merkel cell carcinoma in March, has now been approved in Europe to treat that cancer.
Pfizer and Merck KGaA are officially fourth to market with their checkpoint inhibitor avelumab—but first with to target a rare, aggressive form of skin cancer.